WESTERN STATES CANCER RESEARCH NCORP

DENVER, CO

OncologymRNAPhase II

What changed

Phase II trial registered: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

2d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

91no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,012 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $632k · non-dilutive
Dec 16, 2024
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WANG, LILI · NCI · award ends Nov 30, 2029 · Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation
NIH RePORTER · NIH RePORTER 11248368 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 1, 2023
Chronic Lymphocytic Leukemia, COVID-19 Infection · SUSPENDED · sponsor: City of Hope Medical Center · A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov · NCT05672355 (opens the source filing in a new tab)
Grant
R01 · $503k · non-dilutive
Jul 1, 2023
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WANG, LILI · NCI · award ends Jun 30, 2028 · Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia
NIH RePORTER · NIH RePORTER 11526589 (opens the source filing in a new tab)
Grant
R01 · $308k · non-dilutive
Jun 1, 2023
OREGON HEALTH & SCIENCE UNIVERSITY · PI XIA, ZHENG · NIGMS · award ends May 31, 2027 · Characterizing phenotype-associated subpopulations from single-cell sequencing data
NIH RePORTER · NIH RePORTER 11381880 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 26, 2021
Mantle Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: City of Hope Medical Center · Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
ClinicalTrials.gov · NCT04783415 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 16, 2021
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia · ACTIVE_NOT_RECRUITING · sponsor: City of Hope Medical Center · Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
ClinicalTrials.gov · NCT04657094 (opens the source filing in a new tab)
Trial
PHASE2 registered
May 13, 2020
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: City of Hope Medical Center · Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ClinicalTrials.gov · NCT03961672 (opens the source filing in a new tab)
Trial
PHASE1 registered
Feb 26, 2019
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Richter Syndrome · ACTIVE_NOT_RECRUITING · sponsor: City of Hope Medical Center · Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
ClinicalTrials.gov · NCT03884998 (opens the source filing in a new tab)
Grant
UG1 · $633k · non-dilutive
Aug 1, 2014
WESTERN STATES CANCER RESEARCH NCORP · PI DIBELLA MD, NICHOLAS · NCI · award ends Jul 31, 2026 · NCORP: Colorado Cancer Research Program
NIH RePORTER · NIH RePORTER 11332388 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.30same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
2d agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia
7w agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Characterizing phenotype-associated subpopulations from single-cell sequencing data
8w agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
6mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
6mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Attacking the Tumor Cell-Immune Milieu Interface to Overcome Richter's Transformation
7mo agoGrant renewalSource (opens the source filing in a new tab)
NIH UG1 · $0.6M · NCORP: Colorado Cancer Research Program
11mo agoGrant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

R01 · $632k · non-dilutive

PHASE2 registered

R01 · $503k · non-dilutive

R01 · $308k · non-dilutive

PHASE2 registered

PHASE2 registered

PHASE2 registered

PHASE1 registered

UG1 · $633k · non-dilutive